1
|
Wang Q, Bu Q, Liu M, Zhang R, Gu J, Li L, Zhou J, Liang Y, Su W, Liu Z, Wang M, Lian Z, Lu L, Zhou H. XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression. JHEP Rep 2022; 4:100555. [PMID: 36185574 PMCID: PMC9520276 DOI: 10.1016/j.jhepr.2022.100555] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 08/02/2022] [Accepted: 08/04/2022] [Indexed: 11/27/2022]
Abstract
Background & Aims XBP1 modulates the macrophage proinflammatory response, but its function in macrophage stimulator of interferon genes (STING) activation and liver fibrosis is unknown. X-box binding protein 1 (XBP1) has been shown to promote macrophage nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) activation in steatohepatitis. Herein, we aimed to explore the underlying mechanism of XBP1 in the regulation of STING signalling and the subsequent NLRP3 activation during liver fibrosis. Methods XBP1 expression was measured in the human fibrotic liver tissue samples. Liver fibrosis was induced in myeloid-specific Xbp1-, STING-, and Nlrp3-deficient mice by carbon tetrachloride injection, bile duct ligation, or a methionine/choline-deficient diet. Results Although increased XBP1 expression was observed in the fibrotic liver macrophages of mice and clinical patients, myeloid-specific Xbp1 deficiency or pharmacological inhibition of XBP1 protected the liver against fibrosis. Furthermore, it inhibited macrophage NLPR3 activation in a STING/IRF3-dependent manner. Oxidative mitochondrial injury facilitated cytosolic leakage of macrophage self-mtDNA and cGAS/STING/NLRP3 signalling activation to promote liver fibrosis. Mechanistically, RNA sequencing analysis indicated a decreased mtDNA expression and an increased BCL2/adenovirus E1B interacting protein 3 (BNIP3)-mediated mitophagy activation in Xbp1-deficient macrophages. Chromatin immunoprecipitation (ChIP) assays further suggested that spliced XBP1 bound directly to the Bnip3 promoter and inhibited the transcription of Bnip3 in macrophages. Xbp1 deficiency decreased the mtDNA cytosolic release and STING/NLRP3 activation by promoting BNIP3-mediated mitophagy activation in macrophages, which was abrogated by Bnip3 knockdown. Moreover, macrophage XBP1/STING signalling contributed to the activation of hepatic stellate cells. Conclusions Our findings demonstrate that XBP1 controls macrophage cGAS/STING/NLRP3 activation by regulating macrophage self-mtDNA cytosolic leakage via BNIP3-mediated mitophagy modulation, thus providing a novel target against liver fibrosis. Lay summary Liver fibrosis is a typical progressive process of chronic liver disease, driven by inflammatory and immune responses, and is characterised by an excess of extracellular matrix in the liver. Currently, there is no effective therapeutic strategy for the treatment of liver fibrosis, resulting in high mortality worldwide. In this study, we found that myeloid-specific Xbp1 deficiency protected the liver against fibrosis in mice, while XBP1 inhibition ameliorated liver fibrosis in mice. This study concluded that targeting XBP1 signalling in macrophages may provide a novel strategy for protecting the liver against fibrosis. Macrophage STING signalling can be activated by mtDNA cytosolic leakage from macrophages themselves. Xbp1 depletion suppresses cGAS/STING/NLRP3 activation by restoring BNIP3-mediated mitophagy activation in macrophages. XBP1 targets and inhibits the transcription of Bnip3 directly in macrophages. Myeloid-specific Xbp1 deficiency, or STING deficiency, or Nlrp3 depletion protect livers against fibrosis in mice. Pharmacological inhibition of XBP1 ameliorates liver fibrosis in mice.
Collapse
Key Words
- Acta2/α-SMA, actin, alpha 2, smooth muscle, aorta
- BDL, bile duct ligation
- BMDMs, bone marrow-derived macrophages
- BNIP3
- BNIP3, BCL2/adenovirus E1B interacting protein 3
- CCl4, carbon tetrachloride
- CM, conditional media
- ChIP, chromatin immunoprecipitation
- Col1a1, collagen, type I, alpha 1
- DMXAA, 5,6-dimethylxanthenone-4-acetic acid
- ER, endoplasmic reticulum
- EtBr, ethidium bromide
- HSC, hepatic stellate cell
- IRE1α, inositol-requiring enzyme-1α
- IRF3, interferon regulatory factor 3
- KEGG, Kyoto Encyclopedia of Genes and Genomes
- LC3B, microtubule-associated protein 1 light chain 3 beta
- LPS, lipopolysaccharide
- Liver fibrosis
- MCD, methionine/choline-deficient diet
- Macrophage
- Mitophagy
- MnSOD, manganese superoxide dismutase
- NAFLD, non-alcoholic fatty liver disease
- NASH, non-alcoholic steatohepatitis
- NLRP3, nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3
- PBMCs, peripheral blood mononuclear cells
- ROS, reactive oxygen species
- STING
- STING, stimulator of interferon genes
- TBK1, TANK binding kinase 1
- TGF-β1, transforming growth factor beta 1
- TLR, Toll-like receptor
- TNF-α, tumour necrosis factor alpha
- Timp1, tissue inhibitor of matrix metalloproteinase 1
- WT, wild-type
- XBP1
- XBP1, X-box binding protein 1
- cGAS, cyclic GMP-AMP synthase
- mtDNA
- mtDNA, mitochondrial DNA
- p62, sequestosome 1
- sXBP1, spliced XBP1
- shRNAs, short hairpin RNAs
- uXBP1, unspliced XBP1
Collapse
Affiliation(s)
- Qi Wang
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China.,School of Medicine, Southeast University, Nanjing, China
| | - Qingfa Bu
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Mu Liu
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Rui Zhang
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Jian Gu
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Lei Li
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Jinren Zhou
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Yuan Liang
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Wantong Su
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Zheng Liu
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Mingming Wang
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| | - Zhexiong Lian
- Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Ling Lu
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China.,School of Medicine, Southeast University, Nanjing, China.,Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
| | - Haoming Zhou
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, China
| |
Collapse
|
2
|
Parnigoni A, Caon I, Moretto P, Viola M, Karousou E, Passi A, Vigetti D. The role of the multifaceted long non-coding RNAs: A nuclear-cytosolic interplay to regulate hyaluronan metabolism. Matrix Biol Plus 2021; 11:100060. [PMID: 34435179 PMCID: PMC8377009 DOI: 10.1016/j.mbplus.2021.100060] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 02/03/2021] [Accepted: 02/03/2021] [Indexed: 12/12/2022] Open
Abstract
In the extracellular matrix (ECM), the glycosaminoglycan (GAG) hyaluronan (HA) has different physiological roles favouring hydration, elasticity and cell survival. Three different isoforms of HA synthases (HAS1, 2, and 3) are responsible for the production of HA. In several pathologies the upregulation of HAS enzymes leads to an abnormal HA accumulation causing cell dedifferentiation, proliferation and migration thus favouring cancer progression, fibrosis and vascular wall thickening. An intriguing new player in HAS2 gene expression regulation and HA production is the long non-coding RNA (lncRNA) hyaluronan synthase 2 antisense 1 (HAS2-AS1). A significant part of mammalian genomes corresponds to genes that transcribe lncRNAs; they can regulate gene expression through several mechanisms, being involved not only in maintaining the normal homeostasis of cells and tissues, but also in the onset and progression of different diseases, as demonstrated by the increasing number of studies published through the last decades. HAS2-AS1 is no exception: it can be localized both in the nucleus and in the cytosol, regulating cancer cells as well as vascular smooth muscle cells behaviour. Hyaluronan is a component of the extracellular matrix and is synthetised by three isoenzymes named HAS1, 2, and 3. In several pathologies an upregulation of HAS2 leads to an abnormal accumulation of HA. The long non-coding RNA is a new specific epigenetic regulator of HAS2. In the nucleus HAS2-AS1 modulates chromatin structure around HAS2 promoter increasing transcription. In the cytosol, HAS2-AS1 can interact with several miRNAs altering the expression of several genes as well as can stabilise HAS2 mRNA forming RNA: RNA duplex.
Collapse
Key Words
- 4-MU, 4-methylubelliferone
- 4-MUG, 4-methylumbelliferyl glucuronide
- Atherosclerosis
- Cancer
- ECM, extracellular matrix
- EMT, epithelial to mesenchymal transition
- Epigenetics
- Extracellular matrix
- GAG, glycosaminoglycans
- Glycosaminoglycans
- HA, hyaluronan
- HAS2
- HAS2, hyaluronan synthase 2
- HAS2-AS1
- HAS2–AS1, hyaluronan synthase 2 natural antisense 1
- HIFs, hypoxia-inducible factors
- NF-κB, nuclear factor κ–light-chain enhancer of activated B cell
- PG, proteoglycan
- PTM, post-translational modification
- Proteoglycans
- RBP, RNA-binding protein
- SIRT1, sirtuin 1
- SMCs, smooth muscle cells
- TNF-α, tumour necrosis factor alpha
- UDP-GlcNAc, UDP-N-acetylglucosamine
- UDP-GlcUA, UDP-glucuronic acid
- ceRNA, competitive endogenous RNA
- lncRNA, long non-coding RNA
- miRNA, micro-RNA
Collapse
Affiliation(s)
- Arianna Parnigoni
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| | - Ilaria Caon
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| | - Paola Moretto
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| | - Manuela Viola
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| | - Evgenia Karousou
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| | - Alberto Passi
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| | - Davide Vigetti
- Department of Medicine and Surgery, University of Insubria, via J.H. Dunant 5, 21100 Varese, Italy
| |
Collapse
|
3
|
Oh S, Tsujimoto T, Kim B, Uchida F, Suzuki H, Iizumi S, Isobe T, Sakae T, Tanaka K, Shoda J. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. JHEP Rep 2021; 3:100253. [PMID: 33898958 PMCID: PMC8059085 DOI: 10.1016/j.jhepr.2021.100253] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 01/21/2021] [Accepted: 01/23/2021] [Indexed: 02/07/2023] Open
Abstract
Background & Aims A weight-loss-independent beneficial effect of exercise on non-alcoholic fatty liver disease (NAFLD) management has been reported, but the underlying mechanism is unknown. To help determine this mechanism, the effects of exercise on individual tissues (liver, adipose tissue, and skeletal muscle) were retrospectively studied. Methods Data from Japanese obese men with NAFLD in a 3-month exercise regimen were analysed and compared with those in a 3-month dietary restriction program designed to achieve weight loss. The underlying mechanism was studied in a smaller subcohort. Results Independent of the effect of weight loss, the exercise regimen reduced liver steatosis by 9.5% and liver stiffness by 6.8% per 1% weight loss, and resulted in a 16.4% reduction in FibroScan-AST score. Improvements in these hepatic parameters were closely associated with anthropometric changes (reduction in adipose tissue and preservation of muscle mass), increases in muscle strength (+11.6%), reductions in inflammation and oxidative stress (ferritin: -22.3% and thiobarbituric acid: -12.3%), and changes in organokine concentrations (selenoprotein-P: -11.2%, follistatin: +17.1%, adiponectin: +8.9%, and myostatin: -21.6%) during the exercise regimen. Moreover, the expression of target genes of the transcription factor Nrf2, an oxidative stress sensor, was higher in monocytes, suggesting that Nrf2 is activated. Large amounts of high-intensity exercise were effective at further reducing liver steatosis and potentiating improvements in pathophysiological parameters (liver enzyme activities and organokine profiles). Conclusions The weight-loss-independent benefits of exercise include anti-steatotic and anti-stiffness effects in the livers of patients with NAFLD. These benefits seem to be acquired through the modification of inter-organ crosstalk, which is characterised by improvements in organokine imbalance and reductions in inflammation and oxidative stress. Lay summary We investigated the effects of exercise on non-alcoholic fatty liver disease (NAFLD) that were not related to weight loss. We found that exercise had considerable weight-loss-independent benefits for the liver through a number of mechanisms. This suggests that exercise is important for NAFLD patients, regardless of whether they lose weight. Exercise has effects on liver steatosis and stiffness, independent of weight loss. Exercise maintains muscle mass and alters the secretion of organokines. Exercise increases the phagocytic capacity of Kupffer cells and activates Nrf2. Exercise, especially vigorous exercise, should be used aggressively to manage non-alcoholic fatty liver disease (NAFLD).
Collapse
Key Words
- ALT, alanine aminotransferase
- ANGPTL6, angiopoietin-like 6
- AST, aspartate aminotransferase
- Aerobic exercise
- BDNF, brain-derived neurotrophic factor
- CAP, controlled attenuation parameter
- Dietary restriction
- Elarge, large amount of exercise group
- Esmall, small amount of exercise group
- Esub, exercise (subset for which biological samples were available) group
- Etotal, exercise group
- FAST-Score, FibroScan-AST score
- FGF-21, fibroblast growth factor-21
- FPG, fasting plasma glucose
- GCLC, glutamate-cysteine ligase catalytic subunit
- GCLM, glutamate-cysteine ligase modifier subunit
- GGT, gamma-glutamyl transpeptidase
- GPx, glutathione peroxidase
- HO1, heme oxygenase 1
- HOMA-IR, homeostasis model assessment-insulin resistance
- Hepatokine
- KC, Kupffer cells
- LPS, lipopolysaccharide
- LSM, liver stiffness measured using transient elastography
- Liver fat
- Liver stiffness
- MVPA, moderate-to-vigorous intensity physical activity
- Myokine
- NAFLD, non-alcoholic fatty liver disease
- NASH, non-alcoholic steatohepatitis
- NEFAs, non-esterified fatty acids
- NF-Score, NAFLD fibrosis score
- NQO1, NAD(P)H quinone oxidoreductase
- Nrf2, nuclear factor E2-related factor 2
- Nuclear factor-erythroid 2-related factor 2
- PBMCs, peripheral blood mononuclear cells
- SPARC, secreted protein acidic and rich in cysteine
- Se-P, selenoprotein-P
- TBARS, thiobarbituric acid-reactive substances
- TEI, total energy intake
- TG, triglycerides
- TNF-α, tumour necrosis factor alpha
- VAT, visceral adipose tissue
- WC, waist circumference
- WFA+-M2BP, Wisteria floribunda agglutinin-positive human Mac-2 binding protein
- Wsub, weight-loss (subset for which biological samples were available) group
- Wtotal, weight-loss group
- mnSOD, manganese superoxide dismutase
Collapse
Affiliation(s)
- Sechang Oh
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | | | - Bokun Kim
- Department of Sports Health Care, Inje University, Gimhae, Republic of Korea
| | - Fumihiko Uchida
- Department of Oral and Maxillofacial Surgery, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
| | - Hideo Suzuki
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Seiichiro Iizumi
- Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Tomonori Isobe
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Takeji Sakae
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Kiyoji Tanaka
- Faculty of Health and Sport Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Junichi Shoda
- Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| |
Collapse
|
4
|
Kroll FSA, Putarov TC, Zaine L, Venturini KS, Aoki CG, Santos JPF, Pedrinelli V, Vendramini THA, Brunetto MA, Carciofi AC. Active fractions of mannoproteins derived from yeast cell wall stimulate innate and acquired immunity of adult and elderly dogs. Anim Feed Sci Technol 2020; 261:114392. [PMID: 32288071 PMCID: PMC7126846 DOI: 10.1016/j.anifeedsci.2020.114392] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 01/03/2020] [Accepted: 01/04/2020] [Indexed: 01/15/2023]
Abstract
Aging can promote changes in the immune system in dogs. Nutritional intervention in older dogs aims to increase lifespan. The yeast cell wall comprises β-(1,3)-D-glucan, β-(1,6)-D-glucan and mannoproteins. Elderly dogs when compared to adult dogs had lower absolute T and B lymphocyte counts. Mannoproteins stimulated acquired and innate immune responses in adult and elderly dogs.
Nutritional intervention in older dogs aims to increase lifespan and improve life quality as well as delay the development of diseases related to ageing. It is believed that active fractions of mannoproteins (AFMs) obtained through extraction and fractionation of yeast cell walls (Saccharomyces cerevisiae) may beneficially modulate the immune system. However, studies that have evaluated this component and the effects of ageing on the immune system of dogs are scarce. This study aimed to evaluate the immunological effects of AFMs in adult and elderly dogs. Three extruded iso-nutrient experimental diets were formulated: without addition of AFM (T0); with AFM at 400 mg/kg (T400); and with AFM at 800 mg/kg (T800). Thirty-six beagle dogs were used, and six experimental treatments, resulting in combinations of age (adult and elderly) and diet (T0, T400, and T800), were evaluated. On days zero, 14, and 28, blood samples were obtained for leucocyte phenotyping and phagocytosis assays. On days zero and 28, a lymphoproliferation test, quantification of reactive oxygen (H2O2) and nitrogen (NO) intermediate production, evaluation of faecal immunoglobulin A (IgA) content, and a delayed cutaneous hypersensitivity test (DCHT) were performed. Statistical analyses were performed with SAS software. Repeated measure variance analyses were performed, and means were compared by the Tukey test. Values of P ≤ 0.05 were considered significant, and values of P ≤ 0.10 were considered tendencies. Dogs fed T400 tended to have higher neutrophilic phagocytic activity than dogs fed T800 (P = 0.073). Regarding reactive oxygen intermediates, bacterial lipopolysaccharide (LPS)-stimulated neutrophils from animals that were fed T400 had a tendency to produce more H2O2 than those from animals fed the control diet (P = 0.093). Elderly dogs, when compared to adult dogs, had lower absolute T and B lymphocyte counts, lower auxiliary T lymphocyte counts, and higher cytotoxic T lymphocyte counts (P < 0.05). A significant effect of diet, age, and time with saline inoculation was noted for the DCHT. There was no effect of diet or age on faecal IgA content in dogs. This study suggests beneficial effects of mannoproteins on the specific and nonspecific immune responses in adult and elderly dogs.
Collapse
Key Words
- AFM, active fraction of mannoproteins
- ALP, alkaline phosphatase
- ALT, alanine aminotransferase
- Ageing
- CBC, complete blood count
- CD21+, B lymphocyte
- CD4+, auxiliary T lymphocyte
- CD5+, total T lymphocyte
- CD8+, cytotoxic lymphocyte
- CO, cells only
- Canine
- DCHT, delayed cutaneous hypersensitivity test
- FOSs, fructooligosaccharides
- GALT, gut-associated lymphoid tissue
- IL-12, interleukin 12
- IgA, immunoglobulin A
- Immunosenescence
- LPS, bacterial lipopolysaccharide
- MOSs, mannanoligosaccharides
- NADPH, reduced nicotinamide adenine dinucleotide phosphate
- NO, nitrogen monoxide
- NOS, nitric oxide synthase
- OD, optical density
- PMA, phorbol myristate acetate
- Saccharomyces cerevisiae
- Senescence
- TNF-α, tumour necrosis factor alpha
- Th1, helper T lymphocyte
Collapse
Affiliation(s)
- F S A Kroll
- Department of Veterinary Clinic and Surgery, Sao Paulo State University, Jaboticabal, Brazil
| | - T C Putarov
- Department of Veterinary Clinic and Surgery, Sao Paulo State University, Jaboticabal, Brazil
| | - L Zaine
- Department of Veterinary Clinic and Surgery, Sao Paulo State University, Jaboticabal, Brazil
| | - K S Venturini
- Department of Veterinary Clinic and Surgery, Sao Paulo State University, Jaboticabal, Brazil
| | - C G Aoki
- Department of Veterinary Clinic and Surgery, Sao Paulo State University, Jaboticabal, Brazil
| | - J P F Santos
- Department of Animal Nutrition and Production, University of Sao Paulo, Pirassununga, Brazil
| | - V Pedrinelli
- Department of Veterinary Clinic, University of Sao Paulo, São Paulo, Brazil
| | - T H A Vendramini
- Department of Animal Nutrition and Production, University of Sao Paulo, Pirassununga, Brazil
| | - M A Brunetto
- Department of Animal Nutrition and Production, University of Sao Paulo, Pirassununga, Brazil
| | - A C Carciofi
- Department of Veterinary Clinic and Surgery, Sao Paulo State University, Jaboticabal, Brazil
| |
Collapse
|
5
|
Stamellou E, Storz D, Botov S, Ntasis E, Wedel J, Sollazzo S, Krämer BK, van Son W, Seelen M, Schmalz HG, Schmidt A, Hafner M, Yard BA. Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation. Redox Biol 2014; 2:739-48. [PMID: 25009775 PMCID: PMC4085349 DOI: 10.1016/j.redox.2014.06.002] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 05/29/2014] [Accepted: 06/02/2014] [Indexed: 11/17/2022] Open
Abstract
Acyloxydiene–Fe(CO)3 complexes can act as enzyme-triggered CO-releasing molecules (ET-CORMs). Their biological activity strongly depends on the mother compound from which they are derived, i.e. cyclohexenone or cyclohexanedione, and on the position of the ester functionality they harbour. The present study addresses if the latter characteristic affects CO release, if cytotoxicity of ET-CORMs is mediated through iron release or inhibition of cell respiration and to what extent cyclohexenone and cyclohexanedione derived ET-CORMs differ in their ability to counteract TNF-α mediated inflammation. Irrespective of the formulation (DMSO or cyclodextrin), toxicity in HUVEC was significantly higher for ET-CORMs bearing the ester functionality at the outer (rac-4), as compared to the inner (rac-1) position of the cyclohexenone moiety. This was paralleled by an increased CO release from the former ET-CORM. Toxicity was not mediated via iron as EC50 values for rac-4 were significantly lower than for FeCl2 or FeCl3 and were not influenced by iron chelation. ATP depletion preceded toxicity suggesting impaired cell respiration as putative cause for cell death. In long-term HUVEC cultures inhibition of VCAM-1 expression by rac-1 waned in time, while for the cyclohexanedione derived rac-8 inhibition seems to increase. NFκB was inhibited by both rac-1 and rac-8 independent of IκBα degradation. Both ET-CORMs activated Nrf-2 and consequently induced the expression of HO-1. This study further provides a rational framework for designing acyloxydiene–Fe(CO)3 complexes as ET-CORMs with differential CO release and biological activities. We also provide a better understanding of how these complexes affect cell-biology in mechanistic terms.
Collapse
Affiliation(s)
- E Stamellou
- Institute for Molecular and Cellular Biology, Mannheim University of Applied Sciences, Mannheim, Germany ; Vth. Medical Department, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg Mannheim, Germany
| | - D Storz
- Vth. Medical Department, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg Mannheim, Germany
| | - S Botov
- Department of Chemistry, University of Cologne, Cologne, Germany
| | - E Ntasis
- Vth. Medical Department, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg Mannheim, Germany
| | - J Wedel
- Vth. Medical Department, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg Mannheim, Germany
| | - S Sollazzo
- Department of Chemistry, University of Cologne, Cologne, Germany
| | - B K Krämer
- Vth. Medical Department, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg Mannheim, Germany
| | - W van Son
- Department of Nephrology, Academic Medical Center, Groningen, The Netherlands
| | - M Seelen
- Department of Nephrology, Academic Medical Center, Groningen, The Netherlands
| | - H G Schmalz
- Department of Chemistry, University of Cologne, Cologne, Germany
| | - A Schmidt
- Department of Chemistry, University of Cologne, Cologne, Germany
| | - M Hafner
- Institute for Molecular and Cellular Biology, Mannheim University of Applied Sciences, Mannheim, Germany
| | - B A Yard
- Vth. Medical Department, Medical Faculty Mannheim, Ruprecht Karls University, Heidelberg Mannheim, Germany
| |
Collapse
|